ROS can contribute to the pathogenesis of NAFLD, and it has been proposed that targeting ROS through heme oxygenase-1-mediated bilirubin production could be a potential therapeutic for NAFLD [39]. The gene discussed is HMOX1; the disease is metabolic dysfunction-associated steatotic liver disease.